Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Meropenem plus vaborbactam

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gram Negative InfectionsRecruiting

Gram Negative InfectionsPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Gram Negative Infections

NCT06828848

Clinical

Trials by Indication[1]

Gram Negative Infections1 trial

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population With Suspected or Confirmed Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

Recruiting· Menarini logo

Menarini·Phase 2·NCT06828848·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meropenem plus vaborbactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meropenem plus vaborbactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meropenem plus vaborbactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Menarini company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Menarini

Related News